Nasrin Abolhasanpour
1 
, Fatemehsadat Syedaghamiri
2, Mojgan Rajabi
3,4, Mojtaba Ziaee
5, Leila Hosseini
6* 1 Research Center for Evidence-Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Neuroscience, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
3 Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5 Medical Plants Research Center, Maragheh University of Medical Science, Maragheh, Iran
6 Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Ischemia-reperfusion injury (IRI) remains a global public health problem, with increasing incidence which is associated with significant morbidity and mortality. The duration of blood flow deprivation is a critical risk factor in conditions such as myocardial infarction (MI), stroke, solid organ transplantation, and hemorrhagic shock. From a pathophysiological perspective, IRI leads to numerous architectural, cellular, and metabolic changes in tissues. Moreover, local and systemic inflammation occurs after reperfusion of ischemic tissue. Clinically, the treatment of cases with IRI is frequently restricted to supportive maneuvers, with no exact target-oriented therapies validated so far. Recent research reveals the efficacy of stem cells as a promising therapeutic approach. Additionally, exosomes have been suggested to exert a significant impact on the stimulation of useful signaling pathways in different cardiovascular diseases. This review provided an overview of the new treatment strategies such as stem cell therapy (SCT) and exosome-based treatments for improving myocardial IRI.